Argenx S.E Dividend yield

Argenx S.E is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Argenx S.E is a company from Belgium and Lux., and his stocks are publicly traded.

Argenx S.E paid a total dividend of 0 million EUR last year, for a market value of 11,374 millions (Market Cap 11,376 millions). Dividend per share of Argenx S.E is 0.00 EUR, and his stock market price 242.00 EUR.

According to the chart below where dividend yield is displayed, Argenx S.E, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from Belgium and Lux., Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of Argenx S.E might harm the evolution of share price if the company is not clearly expanding his business.

In addition, you should compare Argenx S.E dividend yield with other Pharmaceuticals and Biotechnology companies or firms from Belgium and Lux..

Argenx S.E Dividend Payout

About the ability of Argenx S.E to maintain his current dividend of EUR 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Argenx S.E payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.

The following figure shows payout ratios over earnings and cashflow of Argenx S.E, compared againt world market average, Belgium and Lux. companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

Argenx S.E Dividend History

Year	Yield	EUR	Paypout	Shares*
Present	0.00%	0.00	0.00%	47
2019	0.00%	0.00	0.00%	43

*In millions

Argenx S.E Stock performance

Finally, last moth Argenx S.E showed a return of 1.20% compared to a worldwide 3.99% average, and a 3.09% of Health Care firms. Over the last year, the company obtained a 68.50% versus a worldwide performance of a 6.65%. More detailed information can be seen in the following graph for Belgium and Lux. and Pharmaceuticals and Biotechnology firms.